Association between functional FCGR3A F158V and FCGR2A R131H polymorphisms and responsiveness to rituximab in patients with autoimmune diseases: a meta-analysis,The Pharmacogenomics Journal

当前位置： X-MOL 学术 › Pharmacogenomics J. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Association between functional FCGR3A F158V and FCGR2A R131H polymorphisms and responsiveness to rituximab in patients with autoimmune diseases: a meta-analysis
The Pharmacogenomics Journal ( IF 2.9 ) Pub Date : 2023-05-06 , DOI: 10.1038/s41397-023-00308-9
Young Ho Lee ₁ , Gwan Gyu Song ₁

Affiliation

Objectives

To investigate the association between the functional Fc gamma receptor 3 A (FCGR3A) V158F and FCGR2A R131H polymorphisms and rituximab therapy in patients with autoimmune diseases.

Methods

We searched the Medline, Embase, and Cochrane databases for relevant articles. We conducted a meta-analysis of the association between FCGR3A V158F and FCGR2A R131H polymorphisms and responsiveness to rituximab in patients with autoimmune diseases.

Results

Eleven studies, consisting of 661 responders and 267 non-responders for FCGR3A V158F polymorphism and 156 responders and 89 non-responders for FCGR2A R131H polymorphism, were included. The meta-analysis revealed a significant association between the FCGR3A V allele and responsiveness to rituximab (odds ratio [OR] = 1.600, 95% confidence interval [CI] = 1.268–2.018, P < 0.001). Furthermore, associations were found using the dominant and homozygous contrast models. Subgroup analysis showed an association between the FCGR3A V allele and responsiveness to rituximab in European, RA, ITP, small (<50) and large (≥50) groups, and short- (≤6 months) and long-term follow-up periods (≥6 months). These associations were also found in recessive, dominant or homozygous contrast models. Meta-analysis revealed no association between the FCGR2A R allele and responsiveness to rituximab (OR = 1.243, 95% CI = 0.825–1.873, P = 0.229).

Conclusions

We demonstrated that the FCGR3A F158V polymorphism is associated with better responsiveness to rituximab therapy in patients with autoimmune diseases, indicating that individuals carrying the FCGR3A V allele will likely respond better to rituximab. However, FCGR2A R131H polymorphism was not associated with better response to rituximab.

中文翻译：

自身免疫性疾病患者功能性 FCGR3A F158V 和 FCGR2A R131H 多态性与利妥昔单抗反应之间的关联：一项荟萃分析

目标

探讨功能性 Fc γ 受体 3 A ( FCGR3A ) V158F 和FCGR2A R131H 多态性与自身免疫性疾病患者利妥昔单抗治疗之间的关联。

方法

我们检索了 Medline、Embase 和 Cochrane 数据库中的相关文章。我们对FCGR3A V158F 和FCGR2A R131H 多态性与自身免疫性疾病患者对利妥昔单抗的反应之间的关联进行了荟萃分析。

结果

纳入了11 项研究，其中包括 661 名FCGR3A V158F 多态性有反应者和 267 名无反应者，以及 156 名FCGR2A R131H多态性有反应者和 89 名无反应者。荟萃分析显示FCGR3A V 等位基因与利妥昔单抗反应性之间存在显着相关性（比值比 [OR] = 1.600，95% 置信区间 [CI] = 1.268–2.018，P < 0.001）。此外，使用显性和纯合对比模型发现了关联。亚组分析显示，在欧洲、RA、ITP、小组（<50）和大组（≥50）以及短期（≤6 个月）和长期随访期中，FCGR3A V 等位基因与利妥昔单抗反应性之间存在相关性（≥6个月）。在隐性、显性或纯合对比模型中也发现了这些关联。荟萃分析显示FCGR2A R 等位基因与利妥昔单抗反应性之间没有关联（OR = 1.243，95% CI = 0.825–1.873，P = 0.229）。